Skip to main content
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. — Investor Relations & Filings

Ticker · CRDF ISIN · US14147L1089 LEI · 549300AHOLZBHHYFWP04 US Professional, scientific and technical activities
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2023-02-02 Board/Management Inform…
Country US United States of America
Listing US CRDF

About Cardiff Oncology, Inc.

https://cardiffoncology.com/

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies. The company's primary focus is on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor being evaluated in clinical trials. These programs test onvansertib in combination with standard-of-care therapeutics for various cancer indications. The company's strategy is designed to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated February 2, 2023, by Cardiff Oncology, Inc. The key content is the appointment of a new Chief Medical Officer, Dr. Fairooz Kabbinavar, including details of his employment agreement and compensation. The document does not contain financial statements or financial performance data. It primarily announces a change in senior management. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under the category 'Board/Management Information' (MANG). The document length is 7356 characters, which is sufficient to contain detailed information about the management change. Therefore, the appropriate classification is MANG with high confidence.
2023-02-02 English
CARDIFF ONCOLOGY, INC.
Major Shareholding Notification
2023-01-26 English
CARDIFF ONCOLOGY, INC.
Major Shareholding Notification
2023-01-26 English
FORM 4
Director's Dealing
2022-11-29 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text specifically mentions "Item 2.02 Results of Operations and Financial Conditions" and references a press release with financial results for the third quarter ended September 30, 2022. The document is only 3286 characters long and primarily furnishes a press release rather than containing detailed financial statements or analysis itself. According to the MENU VS MEAL RULE, such a short document that announces or furnishes a press release of financial results should be classified as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Earnings Release (ER). It is not a full earnings release but a current report furnishing a press release. Therefore, the best classification is Regulatory Filings (RNS).
2022-11-03 English
10-Q
Interim / Quarterly Report Q3 2022
2022-11-03 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.